Results 31 to 40 of about 12,875 (237)

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

Angewandte Chemie, EarlyView.
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco, Fabio Baroni, Angela Capolupo, Sofia Petrocchi, Jonathan Zöller, Linda Cerofolini, Pasquale Russomanno, Rebecca Calamandrei, Bianca Susini, Siyu Lin, Fabio D'Amici, Enrico Ravera, Julian Langer, Marco Fragai   +13 more
wiley   +2 more sources

Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars [PDF]

Exploration of Musculoskeletal Diseases
Biosimilars are biologic products that provide equal mechanisms and efficacy to that of their original biologic references. This paper aims to provide a comprehensive overview of the numerous ways biosimilars are improving care for individuals living ...
Leticia A. Shea, Jamshaid S. Ahmed
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Ongoing development of guidelines for biosimilar medicines assessment in Uganda: Critical evaluation and recommendations for inclusion [PDF]

, 2020
>Magister Scientiae - MScA Biosimilar is defined as a biologic product that is similar but not identical to the reference/originator biologic product.
Nantongo, Eva
core   +1 more source

Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing

Biomolecules, 2019
Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian ...
Dmitry Karateev, Natalia Belokoneva
doaj   +1 more source

Switching Among Biosimilars: A Review of Clinical Evidence

Frontiers in Pharmacology, 2022
Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati, Brian Godman, Brian Godman, Brian Godman, Marco Gobbi, Silvio Garattini, Rita Banzi   +6 more
doaj   +1 more source

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria

Pharmaceuticals, 2021
The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD).
Konstantin Tachkov, Zornitsa Mitkova, Vladimira Boyadzieva, Guenka Petrova   +3 more
doaj   +1 more source

Tendering and biosimilars: what role for value-added services?

Journal of Market Access & Health Policy, 2020
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and
Steven Simoens, Raymond Cheung
doaj   +1 more source

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

JAAD International, 2020
Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use.
Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP   +8 more
doaj   +1 more source

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme. [PDF]

Clin Pharmacol Ther
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Yiu CH, Ianni BD, Day RO, Raubenheimer J, Lu CY.   +4 more
europepmc   +2 more sources